Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles.
Ionizable lipid
Lipid nanoparticle
NK cell
NK-92
Non-viral
mRNA
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
05 Apr 2023
05 Apr 2023
Historique:
received:
06
11
2022
revised:
16
02
2023
accepted:
04
03
2023
medline:
4
4
2023
pubmed:
11
3
2023
entrez:
10
3
2023
Statut:
ppublish
Résumé
In cancer immunotherapy, therapeutic methods targeting NK are highly expected. NK cell-based therapy using NK-92, a human NK cell line, has been clinically evaluated. Delivering mRNA into NK-92 cells is a potent strategy for enhancing its functions. However, the use of lipid nanoparticles (LNP) for this purpose has not yet been evaluated. We previously developed a LNP that was composed of CL1H6 (CL1H6-LNP) for the efficient delivery of siRNA to NK-92 cells, and the use of this material for delivering mRNA to NK-92 cells is reported in this study. Compared with a DLin-MC3-DMA based LNP, used as a benchmark, the CL1H6-LNP caused a high mRNA expression intensity and a cell transfection efficiency of 100%. The efficient mRNA delivery by this CL1H6-LNP is attributed to the high affinity for NK-92 cells and the intense, rapid fusion with the endosomal membrane. It therefore appears that the CL1H6-LNP could be a useful non-viral vector for modifying the NK-92 functions by mRNA. Our findings also provide some insights into the design and development of LNPs for delivering mRNA to NK-92 and NK cells.
Identifiants
pubmed: 36898618
pii: S0378-5173(23)00230-2
doi: 10.1016/j.ijpharm.2023.122810
pii:
doi:
Substances chimiques
Lipid Nanoparticles
0
RNA, Messenger
0
Liposomes
0
RNA, Small Interfering
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
122810Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Takashi Nakamura reports financial support was provided by Japan Society for the Promotion of Science. Takashi Nakamura reports financial support was provided by Japan Agency for Medical Research and Development. Hideyoshi Harashima reports financial support was provided by Special Education and Research Expenses from the Ministry of Education, Culture, Sports, Science and Technology. Takashi Nakamura has patent pending to Hokkaido University. Taisei Nakade has patent pending to Hokkaido University. Yusuke Sato has patent pending to Hokkaido University. Hideyoshi Harashima has patent pending to Hokkaido University.